QualityDipStocks / Health Care · Pharmaceuticals
Verastem VSTM
Outside our quality screen, so we don’t track its dips. It’s 10% below its 52-week high.
Outside our quality screen, 8% over its Market Value. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $8.85price +8%
- Off 52-wk high
- −10%
- Risk vs market
- Market-likebeta 1.04
52-week range 85% of the way from its 52-week low to its high
Price $9.59Market Value $8.85
1 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for VSTM: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much VSTM moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 5.9× the S&P 500’s.
- Beta vs S&P 500
- 1.04
- Volatility
- 76% vs 13% SPY
- Correlation SPY
- 0.17
- Correlation QQQ
- 0.11
Valuation details
MV $8.85
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
GrowthSales compounded 209% a year from FY2024 to FY2025.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only -108.2× over the last 12 months.
ProfitabilityLost $203M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 35.2% in a year: existing holders are being diluted.
ProfitabilityLoses money at the operating line: −183% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
from SEC filings
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 13.71×
- Price / book
- 24.01×
- Market cap
- $1.2Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $88M
- Sales growth, 12 months
- n/an/m: revenue a year ago near zero
- Sales growth, 3 yrs
- +209.1%/yrfrom FY2024
- Diluted EPS, 12 months
- −$2.42
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$203M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- −182.6%
- Net margin
- n/an/m
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $136M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -108.2×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +35.2%diluted shares vs a year ago
- Stock-based comp
- $10M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Verastem’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
Sales +1775%
- Gross margin88%
- Operating margin−82%
- Return on invested capital−375%
- Return on equity−471%
- Sales growth (latest quarter vs year-ago quarter)+1775%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $9.59
- 52-wk lowlowest close, 1 year$3.45−64.0%
- Market Valueavg paid since Oct 14$8.85−7.7%
- PriceMon Nov 2 close$9.59you are here
- 52-wk highhighest close, 1 year$10.64+10.9%
Momentum & 52-week range
RSI 59 · 5 days −4.1%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, after the close
- Consensus EPS($0.44)
- Year-ago EPS($1.35)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
VSTM is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Verastem in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.